Loading clinical trials...
Loading clinical trials...
Prospective Observational Monocentric Study to Evaluate the Impact of the HER2DX Assay on Treatment Decisions in Patients With Early Stage HER2+ Breast Cancer: the HER2-BREAST-DX
To prospectively evaluate the impact of HER2DX on the decision-making processes of the treating physicians and especially among the routine multidisciplinary tumour board, in defining type and setting of systemic therapy administration in patients with stage I-III HER2+ BC, and the degree of clinician's confidence in the treatment recommendation.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Istituto Europeo di Oncologia
Milan, Italy, Italy
Start Date
October 24, 2024
Primary Completion Date
November 1, 2027
Completion Date
November 1, 2027
Last Updated
February 11, 2026
60
ESTIMATED participants
Neoadjuvant standard treatment for HER2+
DRUG
Adjuvant standard treatment for HER2+
DRUG
Lead Sponsor
European Institute of Oncology
NCT06970912
NCT06890221
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions